-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
June 30, 2021/Bio Valley BIOON/ - Colorectal cancer responds differently to immune checkpoint blocking therapies, and this may be partly due to the high tumor mutation burden (TMB)
Image source: https://#%20
Colorectal cancer is commonly known as bowel cancer, which is cancer that occurs in the colon or rectum.
In the article, the researchers selected more than 700 cancer tissue samples and surrounding non-cancerous cell samples from 29 patients receiving immune checkpoint blocking therapy for research (this research is part of the international clinical trial research).
Researchers have found that there are many factors that affect whether immunotherapy can effectively treat patients
High-resolution imaging of colorectal cancer reveals the CD74+ macrophage population (background image), CD8+GzB+ and CD8+Ki67+ T cell interaction maps (enlarged image)
Image source: Michele Bortolomeazzi, et al.
Researcher Francesca said that the results of this article will help clinicians to screen out patients who can respond to immune checkpoint inhibitors before giving them treatment, so as to maximize the benefits of treatment; and this is what researchers currently want to solve The problem provides new opportunities.
In summary, this study clarifies the limitations of TMB as a predictor of colorectal cancer response to anti-PD1 immunotherapy.
Original source:
Original source:Michele Bortolomeazzi, Mohamed Reda Keddar, Lucia Montorsi, et al.
Michele Bortolomeazzi, Mohamed Reda Keddar, Lucia Montorsi, et al.
Immunogenomics of colorectal cancer response to checkpoint blockade: analysis of the KEYNOTE 177 trial and validation cohorts, Gastroenterology(2021).
DOI: 10.
1053/j.
gastro.
2021.
06.
064
